RNAimmune develops mRNA therapeutics and vaccines using a platform that integrates proprietary delivery and AI antigen‑prediction technologies. The company holds a global exclusive right to Sirnaomics’ Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery and has developed an AI algorithm (ALEPVA) for antigen prediction and vaccine design. Since its founding in early 2020, RNAimmune has built an mRNA vaccine and drug discovery and development platform targeting infectious diseases, cancer, and rare diseases. The company is in the IND‑enabling stage for its lead COVID‑19 mRNA vaccine and plans to file an IND with the U.S. FDA before the end of 2021, and is advancing a RAS tumor vaccine program in collaboration with UCLA. Headquartered in Gaithersburg, Maryland, RNAimmune also operates a China R&D center on Guangzhou Bio‑Island. The company intends to use the new financing to accelerate R&D across its vaccine and drug discovery programs. RNAimmune is a biopharmaceutical company that develops mRNA-based therapeutics and vaccines. A spin-off from Sirnaomics and led by founder and CEO Dr. Dong Shen, the company is based in Gaithersburg, Maryland. RNAimmune leverages mRNA as a data carrier to instruct the body to produce proteins and has a global exclusive right to Sirnaomics’ Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. The company has also developed a proprietary AI algorithm, ALEPVA, for antigen prediction and vaccine design. By integrating multiple platform technologies, it aims to build a comprehensive mRNA drug discovery and development platform to advance programs against viral infections, cancer, and rare diseases. Proceeds from its most recent financing will be used to advance its COVID-19 vaccine candidate RV1730 and neoantigen-based cancer vaccine programs.

Total raised

$12M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2021